JPRN-jRCT2033200314招募中3 期
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn's Disease over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks
Shikamura Mitsuhiro0 个研究点目标入组 20 人开始时间: 2021年1月20日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 4age old 至 < 18age old（—）
- 性别
- All
入选标准
- •1. Has a CD diagnosis based on accepted clinical, endoscopic, histological and/or radiologic criteria at least 6 months before the screening visit.
- •2. Has complex perianal fistula refractory to at least one of the following treatments: immunosuppressants or biologics (anti-tumor necrosis factor[TNF]s, anti-integrin, anti-interleukin [IL] 12/23). Fistula(s) refractory to therapy are defined in this study as follows: Immunosuppressants: Inadequate response after 3 months, based on clinical assessment, or more treatment with azathioprine, 6-mercaptopurine or methotrexate. Biologics: Inadequate response after 14 weeks (16 weeks for anti-IL 12/23), based on clinical assessment, or more standard treatment for induction and maintenance.
- •3. A complex perianal fistula(s) that meets one or more of the following criteria, modified from the American Gastroenterological Association (AGA) technical review: High intersphincteric, transsphincteric, extrasphincteric, or suprasphincteric as assessed by magnetic resonance imaging (MRI). Presence of 2-3 external openings (tracts) as assessed by clinical examination. Associated fluid collections as determined by MRI.
- •This study requires that the participant has complex perianal fistulas with a maximum of 2 internal openings and a maximum of 3 external openings, based on clinical assessment. Darvadstrocel treatment is targeted for fistulas that connect between internal and external openings. A central reading of a locally performed pelvic MRI will be performed to confirm the location of the fistula and potential associated perianal abscess(es). Fistulas must have been draining for at least 6 weeks before the screening visit. Participants with actively draining simple subcutaneous fistulas, at the time of the screening visit, are not allowed in this study.
- •4. Has inactive or mildly active luminal CD defined by meeting all of the following criteria:
- •a. Colonoscopy, flexible sigmoidoscopy or rectoscopy performed either at screening or within the 6 months before screening, demonstrating no rectal ulcers larger than 0.5 cm. A participant who has documented rectal ulcers larger than 0.5 cm within the 6 months before screening but has undergone subsequent treatment may be eligible if there are no rectal ulcers larger than 0.5 cm on a sigmoidoscopy or rectoscopy performed after treatment or at the time of screening.
- •b. The improvement of, or no worsening in stool frequency, sustained for 1 week or more, in the interval between the colonoscopy, flexible sigmoidoscopy or rectoscopy in inclusion criteria 4(a) and the screening visit.
- •c. No initiation or intensification of treatment with corticosteroids, immunosuppressants, or monoclonal antibody dose regimen between the colonoscopy, flexible sigmoidoscopy or rectoscopy in inclusion criteria 4(a) and the screening visit.
排除标准
- •1. Has received any investigational compound within 12 weeks/84 days before screening.
- •2. Has received darvadstrocel/expanded adipose-derived mesenchymal stem cells(eASC) in a previous clinical study or as a therapeutic agent.
- •3. The participant weighs <10 kg at screening.
- •4. Has concomitant perianal fistula(s) with only internal or external opening(s).
- •5. Has concomitant internal fistula(s) such as ileo-vesical, rectovaginal or ileo-colonic fistula(s).
- •6. Has an abscess>2 cm, unless resolved in the preparation procedure.
- •7. Has rectal and/or anal stenosis, and/or active proctitis, which would restrict the surgical procedure.
- •8. The participant underwent surgery for the fistula other than drainage or seton placement.
- •9. Has diverting stomas.
- •10. Has ongoing systemic corticosteroid treatment or has been treated with systemic corticosteroids within 4 weeks before screening.
- •11. The participant requires new treatment with immunosuppressants/anti-TNF agents during the screening period.
- •12. The participant has known or suspected COVID-19 by the investigator within the past 2 months (additional testing may be performed at the discretion of the investigator). Positive antibody testing for COVID without other evidence of current or recent active infection does not exclude participation. Participants who were in screening at the time that COVID-19-related factors resulted in discontinuation may also be rescreened with approval of the sponsor or designee.
- •13. The participant requires surgery in the perianal region for reasons other than fistulas at the time of screening or foreseen either during the study and/or during the 24 weeks after treatment administration.
- •14. Has malignant tumor or a prior history of any malignant tumor, including any type of fistula carcinoma.
- •15. Has current or recent (within 3 months before the screening) history of abnormal, severe, progressive, uncontrolled hepatic, hematologic, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.
- •16. Has either congenital or acquired immunodeficiencies, including participants known to be HIV carriers or participants with, in the judgment of the investigator, are suspected to have monogenic inflammatory bowel disease.
- •17. Has previously received a bone marrow transplant.
- •18. Has a contraindication to MRI scan, or other planned study procedures.
- •19. Has a contraindication to the anesthetic procedure.
- •20. Had major surgery or severe trauma within 6 months before the screening visit.
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or HemodialysisEUCTR2013-002610-13-DEAbbVie Deutschland GmbH & Co. KG12
进行中（未招募）
1 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn’s Disease.EUCTR2020-003193-48-NLTakeda Development Center Americas, Inc.20
进行中（未招募）
不适用
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or HemodialysisEUCTR2013-002610-13-PTAbbVie Deutschland GmbH & Co. KG12
尚未招募
3 期
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn's Disease over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks.Anal Passages/Openings with Crohn's DiseaseComplex Perianal Fistulas with Crohn's Disease10002112NL-OMON55133Takeda5
招募中
1 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn's Disease.Complex Perianal Fistulas in Crohn's DiseaseMedDRA version: 20.1Level: LLTClassification code: 10068659Term: Perianal fistula Class: 10017947CTIS2023-503973-39-00Takeda Development Center Americas Inc.20